Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis

Author:

Kishi Takayuki1ORCID,Warren-Hicks William23,Bayat Nastaran1,Targoff Ira N45,Huber Adam M6,Ward Michael M7ORCID,Rider Lisa G1,

Affiliation:

1. Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD

2. Social & Scientific Systems, Inc, Durham, NC

3. EcoStat, Inc., Mebane, NC

4. VA Medical Center, University of Oklahoma Health Sciences Center

5. Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

6. IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada

7. National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA

Abstract

Abstract Objective A North American registry of JDM patients was examined for frequency of and factors associated with corticosteroid discontinuation, complete clinical response and remission. Methods We evaluated probability of achieving final corticosteroid discontinuation, complete clinical response and remission in 307 JDM patients by Weibull time-to-event modelling; conditional probability of complete clinical response and remission using Bayesian network modelling; and significant predictors with multivariable Markov chain Monte-Carlo Weibull extension models. Results The probability of corticosteroid discontinuation was 56%, complete clinical response 38% and remission 30% by 60 months after initial treatment in 105 patients. The probability of remission was conditional on corticosteroid discontinuation and complete clinical response. Photosensitivity, contractures and a longer time to complete clinical response were predictive of the time to final corticosteroid discontinuation. Anti-MJ (NXP2) autoantibodies and a Northwest residential geoclimatic zone were predictive of shorter time to complete clinical response, while dysphonia, contractures, an increase in medications within 24 months and a longer time to corticosteroid discontinuation were associated with longer time to complete clinical response. Anti-p155/140 (TIF1) autoantibodies, an increase in medications within 12–24 months, or longer times to corticosteroid discontinuation and complete clinical response were associated with longer time to remission. Conclusion JDM patients achieve favourable outcomes, including corticosteroid discontinuation, complete clinical response and remission, although timelines for these may be several years based on time-dependent analyses. These outcomes are inter-related and strong predictors of each other. Selected clinical features and myositis autoantibodies are additionally associated with these outcomes.

Funder

Intramural Research Program of the National Institute of Environmental Health Sciences

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institutes of Health

statistical support contract with Social & Scientific Systems, Inc

The Myositis Association and by Tokyo Women’s Medical University

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference43 articles.

1. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes;Rider;J Intern Med,2016

2. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort;Tansley;J Autoimmun,2017

3. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial;Ruperto;Lancet,2016

4. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference;Huber;Arthritis Care Res (Hoboken),2010

5. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis;Wallace;J Rheumatol,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3